The Story of Ammonia in Liver Disease: An Unraveling Continuum

被引:5
作者
Anand, Anil C. [1 ]
Acharya, Subrat K. [2 ,3 ]
机构
[1] Kalinga Inst Med Scinces, Bhubaneswar, India
[2] KIIT Univ, Fortis Escorts Hosp, New Delhi, India
[3] KIIT Univ, Bhubaneswar 751024, India
关键词
ammonia; acute liver failure; cACLD (compensated advanced chronic liver disease); MASLD (metabolic dysfunction-associated steatotic liver disease); HE (hepatic encephalopathy); FULMINANT HEPATIC-FAILURE; AMINO-ACID-METABOLISM; BLOOD AMMONIA; NITROGEN-METABOLISM; ARTERIAL AMMONIA; FATTY LIVER; INTRACRANIAL HYPERTENSION; EARLY INDICATORS; PLASMA AMMONIA; UREA SYNTHESIS;
D O I
10.1016/j.jceh.2024.101361
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hyperammonemia and liver disease are closely linked. Most of the ammonia in our body is produced by transamination and deamination activities involving amino acid, purine, pyrimidines, and biogenic amines, and from the intestine by bacterial splitting of urea. The only way of excretion from the body is by hepatic conversion of ammonia to urea. Hyperammonemia is associated with widespread toxicities such as cerebral edema, hepatic encephalopathy, immune dysfunction, promoting fibrosis, and carcinogenesis. Over the past two decades, it has been increasingly utilized for prognostication of cirrhosis, acute liver failure as well as acute on chronic liver failure. The laboratory assessment of hyperammonemia has certain limitations, despite which its value in the assessment of various forms of liver disease cannot be negated. It may soon become an important tool to make therapeutic decisions about the use of prophylactic and definitive treatment in various forms of liver disease.
引用
收藏
页数:18
相关论文
共 171 条
[1]   Ammonium metabolism in humans [J].
Adeva, Maria M. ;
Souto, Gema ;
Blanco, Natalia ;
Donapetry, Cristobal .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2012, 61 (11) :1495-1511
[2]   Early indicators of prognosis in fulminant hepatic failure: An assessment of the King's criteria [J].
Anand, AC ;
Nightingale, P ;
Neuberger, JM .
JOURNAL OF HEPATOLOGY, 1997, 26 (01) :62-68
[3]  
Anand AC, 2017, J CLIN EXP HEPATOL, V7, P340, DOI 10.1016/j.jceh.2017.11.001
[4]   Activation of Gcn2 in response to different stresses [J].
Anda, Silje ;
Zach, Robert ;
Grallert, Beata .
PLOS ONE, 2017, 12 (08)
[5]  
[Anonymous], Rare disease database: pyruvate carboxylase deficiency
[6]   Drug Therapy: Rifaximin [J].
Bajar, Jasmohan S. ;
Riggio, Olivier .
HEPATOLOGY, 2010, 52 (04) :1484-1488
[7]   Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease [J].
Balcar, Lorenz ;
Krawanja, Julia ;
Scheiner, Bernhard ;
Paternostro, Rafael ;
Simbrunner, Benedikt ;
Semmler, Georg ;
Jachs, Mathias ;
Hartl, Lukas ;
Staettermayer, Albert Friedrich ;
Schwabl, Philipp ;
Pinter, Matthias ;
Szekeres, Thomas ;
Trauner, Michael ;
Reiberger, Thomas ;
Mandorfer, Mattias .
JHEP REPORTS, 2023, 5 (04)
[8]  
Ballester Maria Pilar, 2023, J Hepatol, V79, P967, DOI 10.1016/j.jhep.2023.05.022
[9]   EXCRETION OF HIPPURIC-ACID DURING SODIUM BENZOATE THERAPY IN PATIENTS WITH HYPERGLYCINEMIA OR HYPERAMMONEMIA [J].
BARSHOP, BA ;
BREUER, J ;
HOLM, J ;
LESLIE, J ;
NYHAN, WL .
JOURNAL OF INHERITED METABOLIC DISEASE, 1989, 12 (01) :72-79
[10]   Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure [J].
Bernal, William ;
Hall, Catherine ;
Karvellas, Constantine J. ;
Auzinger, Georg ;
Sizer, Elizabeth ;
Wendon, Juba .
HEPATOLOGY, 2007, 46 (06) :1844-1852